Alembic Q4 FY26 Results: PAT Rs 67 Cr
- May 20, 2026
- Posted by: Neeraj Pandey
- Category: Uncategorized
Alembic Q4 FY26 results were declared on May 19, 2026. Alembic reported PAT of Rs 67 crore down 1.5% YoY from Rs 68 crore in Q4 FY25, on revenue of Rs 60 crore for the quarter ended March 31, 2026. Alembic is a Pharmaceuticals company listed on Indian stock exchanges. This article covers the complete Alembic Q4 FY26 financial highlights, key performance factors, and FY27 outlook for investors tracking Alembic.
Click Here – Get Free Investment Predictions
Alembic Q4 FY26 Financial Highlights
| Metric | Q4 FY26 | Notes |
|---|---|---|
| PAT | Rs 67 crore | down 1.5% YoY from Rs 68 crore in Q4 FY25 |
| Revenue | Rs 60 crore | for the quarter ended March 31, 2026 |
Alembic Q4 FY26 Performance Analysis
The Alembic Q4 FY26 results reflect Alembic’s operational performance during the January to March 2026 quarter. The company operates in the Pharmaceuticals space, a sector supported by India’s strong GDP growth and domestic demand. The Q4 FY26 results demonstrate continued business execution and operational resilience.
Screen the best stocks on the Univest Screener.
Investors tracking the firm will focus on FY27 revenue guidance, margin trajectory, and management’s capital allocation commentary. Track Alembic on the Univest Screener for live fundamentals and real-time updates.
Key Business Factors for the company
Revenue and Operational Performance
the listed company performance reflects the January to March 2026 quarter, historically the year-end quarter with strong order execution and seasonality effects. India’s macroeconomic environment with GDP growth above 6.5% provided a constructive backdrop for the Pharmaceuticals sector during this period.
Profitability and Margin Trends
the group PAT of Rs 67 crore down 1.5% YoY from Rs 68 crore in Q4 FY25. Sustaining profitability and improving operating margins will be key watchpoints for FY27 performance.
India Economic Context for Alembic
The January to March 2026 quarter saw strong domestic consumption, fiscal year-end capital expenditure cycles, and government infrastructure spending. The Reserve Bank of India’s supportive monetary stance and India’s resilient growth trajectory provided a stable environment for listed companies across sectors. For Alembic, operating in the Pharmaceuticals space, this macro backdrop supported demand conditions during the quarter.
FY27 Outlook and Growth Drivers
Following the business results, management commentary on FY27 revenue guidance, capex plans, and order pipeline will be the primary catalysts for investor sentiment. The Pharmaceuticals sector continues to benefit from India’s structural growth, rising domestic consumption, and government policy support.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Frequently Asked Questions on the firm
What is the group PAT?
Ans. it PAT was PAT of Rs 67 crore down 1.5% YoY from Rs 68 crore in Q4 FY25. Results declared May 19, 2026. Verify from NSE/BSE filings before making investment decisions.
What is the business revenue?
Ans. the firm revenue from operations was Rs 60 crore for the quarter ended March 31, 2026. Check the Univest Screener for live data.
When were the company results announced?
Ans. the company results were announced on May 19, 2026, at the board of directors meeting approving audited Q4 and FY26 financial statements.
Is Alembic a good investment after Q4 FY26?
Ans. Investment decisions require individual assessment of fundamentals, valuation, risk tolerance, and investment horizon. This article is for educational purposes only. Consult a SEBI-registered financial advisor before investing.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.
